KLI

Real-life effectiveness and safety of tofacitinib treatment in patients with ulcerative colitis: a KASID multicenter cohort study

Metadata Downloads
Abstract
Background: Tofacitinib is a small molecule that inhibits Janus kinase and has been reported to be effective in Western patients with ulcerative colitis (UC). However, the real-life data on tofacitinib in Asian UC patients are limited.

Objective: To investigate the real-life effectiveness and safety of tofacitinib induction and maintenance treatment in Korean patients with UC.

Design: This was a retrospective study on patients with UC who received tofacitinib treatment at 12 hospitals in Korea between January 2018 and November 2020.

Methods: Clinical remission at week 52, defined as a partial Mayo score of ⩽2 with a combined rectal bleeding subscore and stool frequency subscore of ⩽1, was used as the primary outcome. Adverse events (AEs), including herpes zoster and deep vein thrombosis, were also evaluated.

Results: A total of 148 patients with UC were started on tofacitinib. Clinical remission rates of 60.6%, 54.9%, and 52.8% were reported at weeks 16, 24, and 52, respectively. Clinical response rates of 71.8%, 67.6%, and 59.9% were reported at weeks 16, 24, and 52, respectively. Endoscopic remission rates at weeks 16 and 52 were 52.4% and 30.8% based on the Mayo endoscopic subscore and 20.7% and 15.2% based on the UC endoscopic index of severity (UCEIS), respectively. A higher UCEIS at baseline was negatively associated with clinical response [adjusted odds ratio (aOR): 0.774, p = 0.029] and corticosteroid-free clinical response (aOR: 0.782, p = 0.035) at week 52. AEs occurred in 19 patients (12.8%) and serious AEs in 12 patients (8.1%). Herpes zoster occurred in four patients (2.7%). One patient (0.7%) suffered from deep vein thrombosis.

Conclusions: Tofacitinib was an effective induction and maintenance treatment with an acceptable safety profile in Korean patients with UC.
Author(s)
Seung Hwan ShinKyunghwan OhSung Noh HongJungbok LeeShin Ju OhEun Soo KimSoo-Young NaSang-Bum KangSeong-Joon KohKi Bae BangSung-Ae JungSung Hoon JungKyeong Ok KimSang Hyoung ParkSuk-Kyun YangChang Hwan ChoiByong Duk Ye
Issued Date
2023
Type
Article
Keyword
effectivenesssafetytofacitinibulcerative colitis
DOI
10.1177/17562848231154103
URI
https://oak.ulsan.ac.kr/handle/2021.oak/17431
Publisher
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY
Language
영어
ISSN
1756-283X
Citation Volume
16
Citation Number
1
Citation Start Page
1
Citation End Page
15
Appears in Collections:
Medicine > Nursing
공개 및 라이선스
  • 공개 구분공개
파일 목록
  • 관련 파일이 존재하지 않습니다.

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.